BeOne Medicines (NASDAQ:ONC) Price Target Raised to $410.00 at Guggenheim

BeOne Medicines (NASDAQ:ONC) had its price objective increased by equities research analysts at Guggenheim from $400.00 to $410.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 27.15% from the stock’s previous close.

Several other brokerages also recently commented on ONC. Citigroup upped their price target on shares of BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Sanford C. Bernstein raised BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a research note on Monday, January 12th. Citizens Jmp increased their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $425.00 target price on shares of BeOne Medicines in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $387.08.

BeOne Medicines Price Performance

NASDAQ:ONC traded up $0.08 during mid-day trading on Friday, reaching $322.45. 113,885 shares of the stock were exchanged, compared to its average volume of 280,048. BeOne Medicines has a 1-year low of $196.45 and a 1-year high of $385.22. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average price of $336.79 and a 200 day moving average price of $330.22. The firm has a market capitalization of $35.36 billion, a PE ratio of 632.25 and a beta of 0.52.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. BeOne Medicines had a return on equity of 5.52% and a net margin of 1.38%. Research analysts expect that BeOne Medicines will post -5.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Chan Henry Lee sold 1,660 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total value of $580,203.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John Oyler sold 75,631 shares of BeOne Medicines stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $307.79, for a total value of $23,278,465.49. Following the completion of the transaction, the chief executive officer owned 24,369 shares in the company, valued at $7,500,534.51. The trade was a 75.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 102,656 shares of company stock valued at $31,567,496. Company insiders own 6.62% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. EFG International AG bought a new position in BeOne Medicines in the fourth quarter worth $25,000. Anchor Investment Management LLC bought a new stake in BeOne Medicines in the second quarter valued at about $26,000. Leonteq Securities AG acquired a new position in BeOne Medicines in the fourth quarter worth about $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines during the second quarter worth about $35,000. Finally, CWM LLC lifted its stake in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the period. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Barclays raised its price target to $405 and kept an “overweight” rating, implying meaningful upside versus current levels. Benzinga
• Positive Sentiment: Reported revenue for Q4 was $1.50B, above the $1.45B consensus — a sign of top-line strength that partially offsets profit concerns. MarketBeat
• Neutral Sentiment: Coverage and analysis pieces are questioning whether the multi-year share gains should be reassessed — useful context but not immediate catalysts. Yahoo Finance
• Neutral Sentiment: Third-party earnings rundowns (Zacks) provide metric comparisons versus estimates and last year, helpful for deeper analysis but not new headline news. Zacks
• Negative Sentiment: EPS missed badly: Q4 EPS was $0.58 versus the $1.60 consensus, a clear negative surprise weighing on near-term sentiment. MarketBeat
• Negative Sentiment: FY2026 revenue guidance was lowered to $6.2–$6.4B vs. the ~$6.5B consensus — guidance shortfall is the primary driver of the share decline. Investing.com
• Negative Sentiment: Market reports note the stock fell after the mixed results and guidance miss; local coverage highlights investor concern despite the company “turning a profit.” Yicai Global
• Neutral Sentiment: Reported short-interest data in filings appears inconsistent/blank (zeros/NaN) and offers no clear signal to explain the move.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.